High Court Decision on Arkansas PBM Law, ERISA Opens Door to State Laws - Bloomberg Law News
High Court ruling allows states to regulate Pharmacy Benefit Managers (PBMs) under ERISA, potentially impacting drug pricing and access.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 7, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. All pharmaceutical manufacturers, including branded and generic drug makers. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Ongoing as states may enact new regulations at any time.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
States can now implement laws regulating PBMs, which may affect drug pricing and access to medications.
Who it affects
All pharmaceutical manufacturers, including branded and generic drug makers.
What you must do
Review state laws regarding PBM regulations and adjust compliance strategies accordingly.
Deadline
Ongoing as states may enact new regulations at any time.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Government approves first-ever med with digital tracking system - ABC7 Eyewitness News
- Pharma loses a court battle in its bid to block states from importing drugs from Canada - statnews.com
- Ohio EPA fines Hikma Pharmaceuticals in Columbus $4,400 for violating hazardous waste laws - dispatch.com
- FDA on the Offense! Targeting Pharmaceutical Company Drug Advertising in Wave of Enforcement Actions - natlawreview.com
- FDA review details use of manufacturing process models in drug applications - RAPS